Dyskeratosis Congenita, Aplastic Anemia
Conditions
Keywords
Dyskeratosis Congenita, Hematopoietic Stem Cell Transplantation, Severe Aplastic Anemia
Brief summary
Transplantation with stem cells is a standard therapy in many centers around the world. Previous experience with stem cell transplantation therapy for leukemias, lymphomas, other cancers, aplastic anemia and other non-malignant diseases, has led to prolonged disease-free survival or cure for some patients. However, the high doses of pre-transplant radiation and chemotherapy drugs used, and the type of drugs used, often cause many side effects that are intolerable for some patients. Slow recovery of blood counts is a frequent complication of high dose pre-transplant regimens, resulting in a longer period of risk for bleeding and infection plus a longer time in the hospital. Recent studies have shown that using lower doses of radiation and chemotherapy (ones that do not completely kill all of the patient's bone marrow cells) before blood or bone marrow transplant, may be a better treatment for high risk patients, such as those with Dyskeratosis Congenita (DC) or Severe Aplastic Anemia(SAA). These low dose transplants may result in shorter periods of low blood counts, and blood counts that do not go as low as with traditional pre-transplant radiation and chemotherapy. Furthermore, in patients with Dyskeratosis Congenita or SAA, the stem cell transplant will replace the blood forming cells with healthy cells. It has recently been shown that healthy marrow can take and grow after transplantation which uses doses of chemotherapy and radiation that are much lower than that given to patients with leukemia. While high doses of chemotherapy and radiation may be necessary to get rid of leukemia, this may not be important to patients with Dyskeratosis Congenita or SAA. The purpose of this research is to see if this lower dose chemotherapy and radiation regimen followed by transplant is a safe and effective treatment for patients with Dyskeratosis Congenita or SAA.
Detailed description
This is an open label, single arm, phase II clinical trial designed to evaluate the safety and efficacy of the treatment regimen. Efficacy will be measured by long-term engraftment of the transplanted cells.The primary endpoint of neutrophil engraftment is defined as an absolute neutrophil count (ANC) \>5 x 108/L (first of three consecutive laboratory measurements on different days) with at least 10% donor cells by day 100. We will evaluate the proportion of success (P) and its 95% confidence interval (CI) for the entire group. The null hypothesis of 90% engraftment will be rejected if 4 or more patients fail to engraft out of 15 evaluable patients. The secondary endpoints of regimen related mortality, acute and chronic graft-versus-host disease (GVHD) and secondary malignancies will be estimated by cumulative incidence treating non-event deaths as a competing risk. Survival will be estimated by Kaplan-Meier methods. Immune reconstitution will be summarized with descriptive statistics. SAA and DC arms will be analyzed separately.
Interventions
DRUGCampath 1H
10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
DRUGCyclophosphamide
7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
DRUGFludarabine
6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
PROCEDURETotal Body Irradiation
1 day before the transplant one dose (200 cGy) of total body irradiation is given
PROCEDUREStem Cell Transplantation
Infusion of stem cells on Day 0.
DRUGantithymocyte globulin
ATG (rabbit) 3 mg/kg for 3 days.
DRUGMethylprednisolone
2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
Sponsors
Masonic Cancer Center, University of Minnesota
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with dyskeratosis congenita (DC) or severe aplastic anemia (SAA) 0-70 years of age with an acceptable hematopoietic stem cell (HSC) donor * HSC source * Human leukocyte antigen (HLA) identical or 1 antigen mismatched sibling or other relative eligible to donate bone marrow (BM), umbilical cord blood (UCB) or mobilized peripheral blood (PB) at cell doses that meet current institutional standards. * HLA identical or up to a 1 antigen mismatched unrelated donor. * Two units of unrelated umbilical cord blood (UCB) that are (a) up to 2 HLA antigens mismatched to the patient (b) up to 2 HLA antigens mismatched to each other, (c) minimum cell dose of ≥ 3.5 x 10\^7 nucleated cells/kg and optimal cell dose ≥ 5 x 10\^7 nucleated cells/kg. * If two units are not available: single unrelated UCB unit selected according to Minnesota Bone Marrow Transplant (BMT) program guidelines * Disease Characteristics for DC (both of the following): * Evidence of BM failure: * Requirement for red blood cell and/or platelet transfusions, * Requirement for granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or erythropoietin, or * Refractory cytopenias defined as two out of three: platelets \<40,000/microliter (uL) or transfusion dependent, Absolute neutrophil count \<500/uL without hematopoietic growth factor support, Hemoglobin \<9g/uL or transfusion dependent * Diagnosis of DC: * A triad of mucocutaneous features: oral leukoplakia, nail dystrophy, abnormal reticular skin hyperpigmentation. * Or one of the following: Short telomeres (under a research study), Dyskerin mutation, Telomerase RNA (TERC) mutation * Disease Characteristics for SAA (both of the following): * Evidence of BM failure: * Refractory cytopenia defined by bone marrow cellularity \<25-50% (with \< 30% residual hematopoietic cells) * Diagnosis of SAA: * Refractory cytopenias defined as two out of three: Platelets \<20,000/uL or transfusion dependent, Absolute neutrophil count \<500/uL without hematopoietic growth factor support, Absolute reticulocyte count \<20,000/uL * Patients with early myelodysplastic features. * Patients with or without clonal cytogenetic abnormalities. Patient
Exclusion criteria
* Patients with one or more of the following: * Decompensated congestive heart failure; left ventricular ejection fraction \<35% * Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy * Carbon Monoxide Diffusing Capacity (DLCO) \<30% predicted, and oxygen requirement * Glomerular filtration rate (GFR) \<30% predicted * Pregnant or lactating female * Active serious infection whereby patient has been on intravenous antibiotics for at least one week prior to study entry. Any patient with AIDS or HIV seropositivity. If recent mold infection e.g. Aspergillus - must have \>30 days of appropriate treatment before HSC transplantation and infection must be controlled and cleared by the Infectious Disease consultant. * Cannot receive total body irradiation (TBI) due to prior radiation therapy * Diagnosis of Fanconi anemia based on diepoxybutane (DEB). * DC patients with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia with \>30 blasts. * History of non hematopoietic malignancy within 2 years except resected basal cell carcinoma or treated carcinoma in situ.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neutrophil Engraftment | Day 100 | Defined as an absolute neutrophil count (ANC) \>5 x 10\^8/L (first of three consecutive laboratory measurements on different days) with at least 10% donor cells by day 100. Demonstrate sustained engraftment after a fludarabine based preparative regimen in patients with dyskeratosis congenita followed by hematopoietic cell transplantation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Chronic GVHD | 6 months | Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host. |
| Incidence of Late Secondary Malignancies | 1 Year | Defined as patients who have a secondary malignancy (cancer) occurring. |
| Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) | Day 100 | Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host. |
| Incidence of Regimen Related Mortality at 100 Days | 100 days | all deaths without previous relapse or progression |
| Overall Survival | Day 100 | Overall survival is defined as time from date of transplant to date of death or censored at the date of last documented contact for patients still alive. |
| Incidence of Pulmonary Complications | 6 Months | Defined as patients who exhibit a pulmonary (lung) adverse event. |
| Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD) | Day 100 | Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Patients With DC Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
Campath 1H: 10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
Cyclophosphamide: 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
Fludarabine: 6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
Total Body Irradiation: 1 day before the transplant one dose (200 cGy) of total body irradiation is given
Stem Cell Transplantation: Infusion of stem cells on Day 0. | 15 |
| Patients With SAA Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
Cyclophosphamide: 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
Fludarabine: 6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
Total Body Irradiation: 1 day before the transplant one dose (200 cGy) of total body irradiation is given
Stem Cell Transplantation: Infusion of stem cells on Day 0.
antithymocyte globulin: ATG (rabbit) 3 mg/kg for 3 days.
Methylprednisolone: 2mg/kg IV is given before each dose of ATG. | 21 |
| Total | 36 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 0 | 1 |
Baseline characteristics
| Characteristic | Patients With DC | Patients With SAA | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 6 Participants | 15 Participants | 21 Participants |
| Age, Categorical >=65 years | 0 Participants | 1 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants | 5 Participants | 14 Participants |
| Sex: Female, Male Female | 5 Participants | 11 Participants | 16 Participants |
| Sex: Female, Male Male | 10 Participants | 10 Participants | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 15 / 15 | 20 / 21 |
| serious Total, serious adverse events | 2 / 15 | 1 / 21 |
Outcome results
Primary
Neutrophil Engraftment
Defined as an absolute neutrophil count (ANC) \>5 x 10\^8/L (first of three consecutive laboratory measurements on different days) with at least 10% donor cells by day 100. Demonstrate sustained engraftment after a fludarabine based preparative regimen in patients with dyskeratosis congenita followed by hematopoietic cell transplantation.
Time frame: Day 100
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Neutrophil Engraftment | 15 Participants |
| Patients With SAA | Neutrophil Engraftment | 20 Participants |
Secondary
Incidence of Chronic GVHD
Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.
Time frame: 6 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Incidence of Chronic GVHD | 0 Participants |
| Patients With SAA | Incidence of Chronic GVHD | 0 Participants |
Secondary
Incidence of Chronic GVHD
Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.
Time frame: 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Incidence of Chronic GVHD | 1 Participants |
| Patients With SAA | Incidence of Chronic GVHD | 2 Participants |
Secondary
Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD)
Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.
Time frame: Day 100
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) | 1 Participants |
| Patients With SAA | Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) | 0 Participants |
Secondary
Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD)
Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.
Time frame: Day 100
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD) | 0 Participants |
| Patients With SAA | Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD) | 0 Participants |
Secondary
Incidence of Late Secondary Malignancies
Defined as patients who have a secondary malignancy (cancer) occurring.
Time frame: 1 Year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Incidence of Late Secondary Malignancies | 0 Participants |
| Patients With SAA | Incidence of Late Secondary Malignancies | 4 Participants |
Secondary
Incidence of Pulmonary Complications
Defined as patients who exhibit a pulmonary (lung) adverse event.
Time frame: 6 Months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Incidence of Pulmonary Complications | 3 Participants |
| Patients With SAA | Incidence of Pulmonary Complications | 3 Participants |
Secondary
Incidence of Regimen Related Mortality at 100 Days
all deaths without previous relapse or progression
Time frame: 100 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Incidence of Regimen Related Mortality at 100 Days | 1 Participants |
| Patients With SAA | Incidence of Regimen Related Mortality at 100 Days | 2 Participants |
Secondary
Overall Survival
Overall survival is defined as time from date of transplant to date of death or censored at the date of last documented contact for patients still alive.
Time frame: 1 Year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Overall Survival | 12 Participants |
| Patients With SAA | Overall Survival | 19 Participants |
Secondary
Overall Survival
Overall survival is defined as time from date of transplant to date of death or censored at the date of last documented contact for patients still alive.
Time frame: Day 100
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients With DC | Overall Survival | 14 Participants |
| Patients With SAA | Overall Survival | 19 Participants |